Compass Pathways' (CMPS) "Buy" Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reaffirmed its “Buy” rating on Compass Pathways. MarketBeat’s analyst consensus is “Moderate Buy,” with an average price target of $23.14.
• Compass Pathways reported a quarterly loss of $0.31 per share, beating analyst estimates of a $0.39 loss; analysts forecast a loss of $0.83 per share for the fiscal year.
• Shares opened at $8.61, compared with a 12-month range of $4.88 to $15.87. The company has a market capitalization of about $1.19 billion.

Compass Pathways (NASDAQ:CMPS - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports.

A number of other equities research analysts have also recently commented on the company. Jefferies Financial Group reissued a "buy" rating on shares of Compass Pathways in a research note on Wednesday, September 9th. Morgan Stanley lifted their price target on Compass Pathways from $17.00 to $18.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Wall Street Zen upgraded shares of Compass Pathways from a "strong sell" rating to a "sell" rating in a research note on Sunday. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Pathways in a research report on Thursday, October 15th. Finally, Oppenheimer restated an "outperform" rating and set a $20.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.14.

Compass Pathways Price Performance

CMPS opened at $8.61 on Monday. The stock has a fifty day simple moving average of $12.32 and a two-hundred day simple moving average of $10.41. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -2.47 and a beta of 2.43. Compass Pathways has a 12-month low of $4.88 and a 12-month high of $15.87.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.08. Research analysts predict that Compass Pathways will post -0.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

Institutional investors have recently made changes to their positions in the business. North Star Investment Management Corp. lifted its position in Compass Pathways by 23.9% during the third quarter. North Star Investment Management Corp. now owns 9,317 shares of the company's stock valued at $116,000 after acquiring an additional 1,800 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock worth $26,000 after buying an additional 1,920 shares during the period. WINTON GROUP Ltd lifted its position in Compass Pathways by 20.1% during the second quarter. WINTON GROUP Ltd now owns 17,900 shares of the company's stock valued at $253,000 after purchasing an additional 3,000 shares during the period. Ancora Advisors LLC purchased a new stake in shares of Compass Pathways in the second quarter worth about $43,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Compass Pathways by 15.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company's stock valued at $317,000 after purchasing an additional 3,249 shares in the last quarter. Institutional investors own 46.19% of the company's stock.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.